June 2024

Stratosvir is pleased to announce Proven Connect (Prostate Cancer Research) has joined Cancer Research Horizons in Stratosvir’s latest funding round to Support Development of Next Generation Viral Immunotherapy Agents to Treat Cancer

Stratosvir is at the forefront of revolutionising viral immunotherapy (the use of viruses to turn the body’s own defences) to treat cancer. Our mission is to harness the power of this modality and to develop safe and accessible breakthrough therapies that can transform the lives of many affected by advanced cancers, especially advanced prostate cancer.

We are thrilled that Proven Connect joins follow on investors Cancer Research Horizons (Cancer Research UK’s innovation arm) and angel investment in Stratosvir’s latest investment round to support our mission to develop:-

1. Groundbreaking Innovation: Advanced solid tumours remain one of the most challenging diseases to treat, but Stratosvir is engineering 3rd generation viruses that can be more effective than current drugs. These will be safe, affordable and can be administered intravenously to deliver immunotherapy to where it is needed.

2. Technology with High Impact Potential: Cancer research is not just about extending life; it’s about enhancing the quality of life. Stratosvir aims to develop treatments that can lead to better outcomes, fewer side effects, and improved patient experiences.

3. Multiple Revenue Opportunities: Stratosvir’s platform will provide pipeline of innovative therapies for advanced cancers (including prostate cancer) an area of significant unmet need.

Stratosvir is currently supported by Cancer Research Horizons, Deep Science Ventures (and partners) and o2h Ventures.